British Columbia Starts Biosimilar Switching Program

 
• By Dave Wallace

The Canadian province of British Columbia has announced a biosimilar switching program for etanercept, infliximab and insulin glargine that will see patients using original biologics switched to biosimilars within six months.

Canada
British Columbia is leading the way on biosimilar switching in Canada • Source: Shutterstock

More from Biosimilars

More from Products